Kura Oncology (NASDAQ:KURA – Free Report) had its price objective boosted by Wedbush from $36.00 to $38.00 in a research note issued to investors on Thursday morning,Benzinga reports. Wedbush currently has an outperform rating on the stock.
Several other research firms also recently weighed in on KURA. Citizens Jmp reiterated a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a research note on Monday, June 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Wells Fargo & Company set a $24.00 price target on shares of Kura Oncology in a research note on Thursday, June 4th. Sanford C. Bernstein set a $24.00 price objective on shares of Kura Oncology in a report on Monday, June 15th. Finally, Jefferies Financial Group set a $24.00 price objective on shares of Kura Oncology in a research note on Thursday, May 28th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $25.62.
Read Our Latest Stock Report on Kura Oncology
Kura Oncology Stock Up 7.6%
Kura Oncology (NASDAQ:KURA – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The company had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. On average, equities research analysts anticipate that Kura Oncology will post -3.3 EPS for the current year.
Insider Buying and Selling
In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of the firm’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $9.82, for a total value of $834,002.78. Following the completion of the transaction, the insider owned 182,345 shares in the company, valued at $1,790,627.90. This trade represents a 31.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.60% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Kura Oncology
A number of large investors have recently modified their holdings of KURA. IFP Advisors Inc grew its stake in Kura Oncology by 115.3% during the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after acquiring an additional 1,284 shares in the last quarter. Allworth Financial LP lifted its stake in Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after purchasing an additional 1,553 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Kura Oncology by 49.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock valued at $60,000 after purchasing an additional 1,888 shares during the period. Insigneo Advisory Services LLC bought a new position in Kura Oncology in the 4th quarter valued at $105,000. Finally, LPL Financial LLC purchased a new position in shares of Kura Oncology during the 4th quarter valued at $105,000.
Kura Oncology News Roundup
Here are the key news stories impacting Kura Oncology this week:
- Positive Sentiment: Quarterly results exceeded expectations: Kura reported a second-quarter loss of $0.77 per share, narrower than the roughly $0.88–$0.89 consensus loss, while revenue of $20.87 million topped estimates of approximately $20.16 million. The earnings beat may have improved sentiment toward the company’s execution. Kura Oncology Q2 earnings report
- Positive Sentiment: Analyst target increased substantially: Wedbush raised its price target from $36 to $38 and maintained an “outperform” rating. The target implies significant potential upside from the recent trading level, supporting bullish investor expectations. Wedbush raises Kura Oncology price target
- Positive Sentiment: Future revenue visibility: Management outlined a potential $90 million–$110 million in collaboration revenue for 2027 and is targeting 2028 topline results from the KOMET-017 study. These milestones could provide catalysts if development and commercial plans remain on track. Kura collaboration revenue and KOMET-017 update
- Neutral Sentiment: Clinical evidence remains under evaluation: Recent coverage examines what Kura’s latest update means for the clinical evidence supporting its pipeline. The implications for valuation depend on the strength and durability of upcoming data. Kura clinical evidence update
- Negative Sentiment: Analyst estimates are not uniformly improving: Brookline Capital Markets reduced its FY2029 EPS forecast to $5.70 from $6.01, while broader coverage describes conflicting analyst sentiment. Kura remains unprofitable, with analysts expecting a full-year loss, which could limit gains if development spending rises or milestones are delayed. Conflicting analyst sentiment on Kura Oncology
Kura Oncology Company Profile
Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.
The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.
Read More
- Five stocks we like better than Kura Oncology
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
